UNICEF signals source agreement with Pfizer for oral COVID-19 therapy – Earth

NEW YORK/COPENHAGEN, 22 March 2022 – UNICEF has signed a offer settlement with Pfizer for the procurement of up to 4 million cure classes of the new oral antiviral drugs nirmatrelvir/ritonavir (PAXLOVID™) in 2022.

UNICEF procurement of nirmatrelvir/ritonavir (PAXLOVID™) is dependent on place desire, clinical suggestions and vital approvals.

In December 2021, the US Foods and Drug Administration issued an Crisis Use Authorization for the use of nirmatrelvir/ritonavir (PAXLOVID™) for the cure of mild to moderate scenarios of COVID-19. Nirmatrelvir/ritonavir (PAXLOVID™) is at the moment under assessment by the Entire world Well being Organization (WHO).

This arrangement will help assure that very low- and center-income nations around the world (LMICs) have timely access to this novel COVID-19 therapeutic. Source will be produced obtainable for procurement and shipping to 95 LMICs, which includes some upper-center income nations around the world. UNICEF will function closely with WHO and Accessibility to COVID-19 Tools Accelerator (ACT-A) partners these as The World-wide Fund and Unitaid to guarantee equitable accessibility to nirmatrelvir/ritonavir (PAXLOVID™).

UNICEF carries on to operate with ACT-A partners and market to aid equitable accessibility to COVID-19 therapeutics.